Cancer and Metastasis Reviews

, Volume 15, Issue 1, pp 77–89 | Cite as

Invasion and metastasis

  • Douglas Boyd
Article

Abstract

The invasive character of squamous cell carcinoma of the head and neck represents a major challenge to the clinician since most often these tumors require extensive surgical resection impairing important physiological functions including speech and swallowing. Additionally, in many cases costly reconstructive surgery is required to repair the adverse cosmetic effects of the resective surgery. Thus, there is an urgent need to understand the molecular mechanism(s) which underlie the local and regional spread of this disease. Since the ability of tumor cells to invade into surrounding structures requires hydrolytic action much effort has been spent on identifying the hydrolases involved in this process. Some of the enzymes which have been implicated in the spread of head and neck cancer include the urokinase-type plasminogen activator and several members of the collagenase family such as type I and IV collagenases and the stromelysins synthesized either by the tumor cells or in the surrounding fibroblasts. More recent studies have addressed the mechanism(s) by which these hydrolases are overexpressed in invasive cancer. In the tumor cells themselves, work has focused on defining the transcriptional requirements for enzyme synthesis and addressing how the appropriate transcription factors are activated by signal transduction pathways. In contrast, where the hydrolases (e.g. stromelysin-2 and stromelysin-3) are produced by the fibroblasts, current investigations are directed at identifying tumor-derived growth factors which lead to the inducible expression of the enzymes in the stromal cells. The ultimate goal of these studies is to develop novel therapeutic interventions which decrease the invasive capacity of head and neck cancer leading to longer survival times and enhanced quality of life for patients afflicted with this disease.

Key words

protease urokinase collagenase signal transduction transcription 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Tryggvason K, Hoyhtya M, Salo T: Proteolytic degradation of extracellular matrix in tumor invasion. Biochim Biophys Acta 907: 191–217, 1987Google Scholar
  2. 2.
    Hirota J, Yoneda K, Osaki T: Basement membrane type IV collagen in oral squamous cell carcinoma. Head and Neck 12: 400–405, 1990Google Scholar
  3. 3.
    Robbins KC, Summaria L, Hsieh B, Shah R: The peptide chains of human plasmin. J Biol Chem 242: 2333–2342, 1967Google Scholar
  4. 4.
    Liotta L, Goldfarb R, Brundage R, Siegel G, Terranova V, Garbisa S: Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res 41: 4629–4636, 1981Google Scholar
  5. 5.
    Salo T, Liotta L, Keski-Oja J, Turpeenniemi-Hujanen T, Tryggvason K: Secretion of basement collagen degrading enzyme and plasminogen activator by transformed cells-Role in metastasis. Int J Cancer 30: 669–673, 1982Google Scholar
  6. 6.
    Ossowski L, Reich E: Antibodies to plasminogen activator inhibit human tumor metastatis. Cell 35: 611–619, 1983Google Scholar
  7. 7.
    Yu H, Schultz R: Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B16 cells transfected with human urokinase sense and antisense genes. Cancer Res 50: 7623–7633, 1991Google Scholar
  8. 8.
    Achbarou A, Kaiser S, Tremblay G, Ste-Marie L, Brodt P, Goltzman D, Rabbani SA: Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res 54: 2372–2377, 1994Google Scholar
  9. 9.
    Sappino A, Belin D, Huarte J, Hirschel-Scholz S, Saurat J, Vassalli J: Differential protease expression by cutaneous squamous and basal cell carcinomas. J Clin Invest 88: 1073–1079, 1991Google Scholar
  10. 10.
    Miller SJ, Jensen PJ, Dzubow LM, Lazarus GS: Urokinase plasminogen activator is immunocytochemically detectable in squamous cell but not basal cell carcinomas. J Invest Dermatology 98: 351–358, 1992Google Scholar
  11. 11.
    Clayman G, Wang SW, Nicolson GL, El-Naggar A, Mazar A, Henkin J, Blasi F, Goepfert H, Boyd D: Regulation of urokinase-type plasminogen activator expression in squamous cell carcinoma of the oral cavity. Int J Cancer 54: 73–80, 1993Google Scholar
  12. 12.
    Bernhard EJ, Muschel RJ, Hughes EN: Mr 92,000 gelatinase release correlates with the metastatic phenotype in transformed rat embryo cells. Cancer Res 50: 3872–3877, 1990Google Scholar
  13. 13.
    Bernhard EJ, Gruber SB, Muschel RJ: Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells. Proc Natl Acad Sci USA 91: 4293–4297, 1994Google Scholar
  14. 14.
    Wilhelm SM, Collier IE, Marmer BL, Eisen AZ, Grant G, Goldberg G: SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages. Degrades type IV collagen. Activation leads to removal of 73 amino acids. Contains zinc-binding domain and fibronectin domain. J Biol Chem 264: 17213–17221, 1989Google Scholar
  15. 15.
    Goldberg G, Strongin A, Collier IE, Genrich T, Marmer BL: Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J Biol Chem 267: 4583–4591, 1992Google Scholar
  16. 16.
    Nakajima M, Welch DR, Wynn DM, Tsuruo T, Nicolson GL: Serum and plasma Mr 92,000 progelatinase levels correlate with spontaneous metastasis of rat 13762NF mammary adenocarcinoma. Cancer Res 53: 5802–5807, 1993Google Scholar
  17. 17.
    Bernhard EJ, Hagner B, Wong C, Lubenski I, Muschel RJ: The effect of E1A transfection on MMP-9 expression and metastatic potential. Int J Cancer 60: 718–724, 1995Google Scholar
  18. 18.
    Pyke C, Ralkiaer E, Huhtala P, Hurskainen T, Dano K, Tryggvason K: Localization of messenger RNA for Mr 72,000 and 92,000 type IV collagenase in human skin cancers by in situ hybridization. Cancer Res 52: 1336–1341, 1992Google Scholar
  19. 19.
    Juarez C, Clayman G, Nakajima M, Tanabe K, Saya H, Nicolson GL, Boyd D: Role and regulation of 92 kDa type IV collagenase (MMP-9) in invasive squamous cell carcinoma of the oral cavity. Int J Cancer 54: 73–80, 1993Google Scholar
  20. 20.
    Garbisa S, Scagliotti G, Di Francesco C, Caenazzo C, Onisto M, Micela M, Stetler-Stevenson WG, Liotta L: Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy. Cancer Res 52: 4548–4549, 1992Google Scholar
  21. 21.
    Frisch SM, Reich R, Collier IE, Genrich LT, Martin G, Goldberg G: Adenovirus E1A represses protease gene expression and inhibits metastasis of human tumor cells. Oncogene 5: 75–83, 1990Google Scholar
  22. 22.
    Watson SA, Morris TM, Robinson G, Crimmin MJ, Brown PD, Hardcastle JD: Inhibiton of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res 55: 3629–3633, 1995Google Scholar
  23. 23.
    Huhtala P, Chow L, Tryggvason K: Structure of the human type IV collagenase gene. J Biol Chem 265: 11077–11082, 1990Google Scholar
  24. 24.
    Collier IE, Bruns GAP, Goldberg GI, Gerhard DS: On the structure and chromosome location of the 72- and 92-kDa human type IV collagenase genes. Genomics 9: 429–434, 1991Google Scholar
  25. 25.
    Overall CM, Wrana JL, Sodek J: Transcriptional and posttranscriptional regulation of 72kDa gelatinase/type IV collagenase by transforming growth factor-beta in human fibroblasts. J Biol Chem 266: 14064–14071, 1991Google Scholar
  26. 26.
    Okada A, Belloco J, Rouyer N, Chenard M, Rio M, Chambon P, Basset P: Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc Natl Acad Sci USA 92: 2730–2734, 1995Google Scholar
  27. 27.
    Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M: A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 370: 61–65, 1994Google Scholar
  28. 28.
    Matrisian LM: The matrix-degrading metalloproteinases. BioEssays 14: 445–463, 1992Google Scholar
  29. 29.
    Muller D, Breathnach R, Engelmann A, Millon R, Bronner G, Flesch H, Dumont P, Eber M, Abecassis J: Expression of collagenase-related metalloproteinase genes in human lung or head and neck tumours. Int J Cancer 48: 550–556, 1991Google Scholar
  30. 30.
    Gray ST, Wilkins RJ, Yun K: Interstitial collagenase gene expression in oral squamous cell carcinoma. American Journal of Pathology 141: 301–306, 1992Google Scholar
  31. 31.
    Muller D, Wolf C, Abecassis J, Millon R, Engelmann A, Bronner G, Rouyer N, Rio M, Eber M, Methlin G et al.: Increased stromelysin 3 gene expression is associated with increased local invasiveness in head and neck squamous cell carcinomas. Cancer Res 53: 165–169, 1993Google Scholar
  32. 32.
    Bejarano PA, Noekken ME, Suzuki K, Hudson BG, Nagase H: Degradation of basement membranes by human matrix metalloproteinase 3 (stromelysin). Biochem J 256: 413–419, 1988Google Scholar
  33. 33.
    Polette M, Clavel C, Muller D, Abecassis J, Binninger I, Birembaut P: Detection of mRNAS encoding collagenase I and stromelysin 2 in carcinomas of the head and neck by in situ hybridization. Invasion Metastasis 11: 76–83, 1991Google Scholar
  34. 34.
    Polette M, Clavel C, Birembaut P, De Clerck YA: Localization by in situ hybridization of mRNAs encoding stromelysin 3 and tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2 in human head and neck carcinomas. Pathology Research and Practice 189: 1052–1057, 1993Google Scholar
  35. 35.
    Hollas W, Hoosein N, Chung LWK, Mazar A, Henkin J, Kariko K, Barnathan E, Boyd D: Expression of urokinase and its receptor in invasive and non-invasive prostate cancer cell lines. Thrombosis and Haemostasis 68: 662–666, 1992Google Scholar
  36. 36.
    Henderson BR, Tansey WP, Phillips SM, Ranshaw IA, Kefford RE: Transcriptional and posttranscriptional activation of urokinase plasminogen activator gene expression in metastatic tumor cells. Cancer Res 52: 2489–2496, 1992Google Scholar
  37. 37.
    Nanbu R, Menoud P, Nagamine Y: Multiple instability-regulating sites in the 3' untranslated region of the urokinasetype plasminogen activator mRNA. Mol Cell Biol 14: 4920–4928, 1995Google Scholar
  38. 38.
    Sato H, Seiki M: Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene 8: 395–405, 1993Google Scholar
  39. 39.
    Huhtala P, Tuuttila A, Chow L, Lohi J, Keski-Oja J, Tryggvason K: Complete structure of the human gene for 92-kDa type IV collagenase. J Biol Chem 266: 16485–16490, 1991Google Scholar
  40. 40.
    Lyons J, Birkedal-Hansen H: Interleukin-1b and transforming growth factor/EGF induce expression of Mr 95,000 type IV collagenase/gelatinase and interstitial fibroblast-type collagenase by rat mucosal keratinocytes. J Biol Chem 268: 19143–19151, 1993Google Scholar
  41. 41.
    Sato H, Kita M, Seiki M: v-src activates the expression of 92-kDa type IV collagenase through the AP-1 site and the GT Box homolgous to retinoblastoma control elements. J Biol Chem 268: 23460–23468, 1993Google Scholar
  42. 42.
    Riccio A, Grimaldi G, Verde P, Sebastio G, Boast S, Blasi F: The human urokinase plasminogen activator gene and its promoter. Nucl Acids Res 13: 2759–2771, 1985Google Scholar
  43. 43.
    Verde P, Boast S, Franze A, Robbiati F, Blasi F: An upstream enhancer and a negative element in the 5′ flanking region of the human urokinase plasminogen activator gene. Nucl Acids Res 16: 10699–10715, 1988Google Scholar
  44. 44.
    Von der Ahe D, Pearson D, Nagamine Y: Macromolecular interaction on a cAMP responsive region in the urokinasetype plasminogen activator gene: a role of protein phosphorylation. Nucleic Acids Research 18: 1991–1999, 1990Google Scholar
  45. 45.
    Menoud P, Matthies R, Hofsteenge J, Nagamine Y: Purification and cDNA cloning of a transcription factor which functionally cooperates within a cAMP regulatory unit in the porcine uPA gene. Nucleic Acids Research 21: 1845–1852, 1993Google Scholar
  46. 46.
    Nerlov C, Rorth P, Blasi F, Johnsen M: Essential AP-l and PEA3 binding elements in the human urokinase enhancer display cell type-specific activity. Oncogene 6: 1583–1593, 1991Google Scholar
  47. 47.
    Verde P, Stoppelli MP, Galeffi P, Di Nocera P, Blasi F: Identification and primary sequence of an unspliced human urokinase poly (A+) RNA. Proc Nat Acad Sci USA 81: 4727–4731, 1984Google Scholar
  48. 48.
    Kasai S, Arimura H, Nishida M, Suyama T: Primary structure of single-chain pro-urokinase. J Biol Chem 260: 12382–12389, 1985Google Scholar
  49. 49.
    Grimaldi G, Di Fiore P, Locatelli EK, Falco J, Blasi F: Modulation of urokinase plasminogen activator gene expression during the transition from quiescent to proliferative state in normal mouse cells. EMBO J 5: 855–861, 1986Google Scholar
  50. 50.
    Rossi P, Grimaldi P, Blasi F, Geremia R, Verde P: Folliclestimulating hormone and cyclic AMP induce transcription from the human urokinase promoter in primary cultures of mouse Sertoli cells. Molecular Endocrinology 4: 940–946, 1990Google Scholar
  51. 51.
    Rorth P, Nerlov C, Blasi F, Johnsen M: Transcription factor PEA3 participates in the induction of urokinase plasminogen activator transcription in murine keratinocytes stimulated with epidermal growth factor or phorbolester. Nucleic Acids Research 128: 5009–5017, 1990Google Scholar
  52. 52.
    Nerlov C, De Cesare D, Pergola F, Carracciolo A, Blasi F, Johnsen M, Verde P: A regulatory element that mediates co-operation between a PEA3-AP-l element and AP-l site is required for phorbol ester induction of urokinase enhancer activity in HepG2 hepatoma cells. EMBO J 11: 4573–4582, 1992Google Scholar
  53. 53.
    Hansen SK, Nerlov C, Zabel U, Verde P, Johnsen M, BAeuerle A, Blasi F: A novel complex between the p65 subunit of NF-kB and c-Rel binds to a DNA element involved in the phorbol ester induction of the human urokinase gene. EMBO J 11: 205–213, 1992Google Scholar
  54. 54.
    De Cesare D, Vallone D, Caracciolo A, Sassone-Corsi P, Nerlov C, Verde P: Heterodimerization of c-jun with ATF-2 and c-fos is required for positive and negative regulation of the human urokinase enhancer. Oncogene 11: 365–376, 1995Google Scholar
  55. 55.
    Kolesnick R, Golde DW: The spingomyelin pathway in tumor necrosis factor and interleukin-l signaling. Cell 77: 325–328, 1994Google Scholar
  56. 56.
    Karin M: Signal transduction from the cell surface to the nucleus through the phosphorylation of transcription factors. Curr Opin Cell Biol 6: 415–424, 1994Google Scholar
  57. 57.
    Pepper MS, Matsumoto K, Nakamura T, Orei L, Montesano R: Hepatocyte growth factor increases urokinasetype plasminogen activator (u-PA) and u-PA receptor expression in Madin-Darby canine kidney epithelial cells. J Biol Chem 267: 20493–20496, 1992Google Scholar
  58. 58.
    Stacey DW, Roudebush M, Day R, Mosser SD, Gibbs JB, Feig LA: Dominant inhibitory ras mutants demonstrate the requirement for ras activity in the action of tyrosine kinase oncogenes. Oncogene 6: 2297–2304, 1991.Google Scholar
  59. 59.
    Graziani A, Gramaglia D, Zonca P, Comoglio PM: Hepatocyte growth factor/scatter factor stimulates the Ras-guanine nucleotide exchanger. J Biol Chem 268: 9165–9168, 1993Google Scholar
  60. 60.
    Sasaoka T, Langlois WJ, Leitner JW, Draznin B, Olefsky JM: The signaling pathway coupling epidermal growth factor receptors to activation of p21ras. J Biol Chem 268: 32621–32625, 1994Google Scholar
  61. 61.
    Kuzumaki N, Ggiso Y, Oda A, Fujita H, Suzuki H, Sato C, Mullauer L: Resistance to oncogenic transformation in revertant R1 of human ras-transformed NIH 3T3 cells. Mol Cell Biol 9: 2258–2263, 1989Google Scholar
  62. 62.
    Huang W, Alessandrini A, Crews CM, Erikson RL: Raf-l forms a stabke complex with Mekl and activates Mekl by serine phosphorylation. Proc Natl Acad Sci USA 90: 10947–10951, 1993Google Scholar
  63. 63.
    Minden A, Lin A, McMahon M, Lange-Carter C, Derijard B, Davis RJ, Johnson GL, Karin M: Differential activation of ERK and JNK mitogen-activated protein kinases by rat-l and MEKK. Science 266: 1719–1722, 1994Google Scholar
  64. 64.
    Bruder JT, Heidecker G, Rapp UR: Serum-, TPA-, and Rasinduced expression from Ap-l/Ets-driven promoters requires Raf-l kinase. Genes and Development 6: 545–556, 1992Google Scholar
  65. 65.
    Kyriakis JM, App H, Zhang X, Banerjee P, Brautigan DL, Rapp UR, Avruch J: Raf-l activates MAP kinase-kinase. Nature 358: 417–420, 1992Google Scholar
  66. 66.
    Crews CM, Alessandrini A, Erikson RL: The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product. Science 258: 478–480, 1992Google Scholar
  67. 67.
    Gille H, Sharrocks AD, Shaw PE: Phosphorylation of transcription factor p62tcf by MAP kinase stimulates ternary complex formation at c-fos promoter. Nature 358: 414–417, 1992Google Scholar
  68. 68.
    Sozeri O, Vollmer K, Liyanage M, Frith D, Kour G, Mark GE, Stabel S: Activation of the c-raf protein kinase by protein kinase C phosphorylation. Oncogene 7: 2259–2262, 1992Google Scholar
  69. 69.
    Lin A, Minden A, Martinetto H, Claret FX, Lange-Carter C, Mercurio F, Johnson GL, Karin M: Identification of a dual specificity kinase that activates the Jun Kinases and p38-Mpk2. Science 268: 286–290, 1995Google Scholar
  70. 70.
    Galang CK, Der CJ, Hauser CA: Oncogenic ras can induce transcriptional activation through a variety of promoter elements. including tandem c-Ets-2 binding sites. Oncogene 9: 2913–2921, 1994Google Scholar
  71. 71.
    Deng T, Karin M: c-Fos transcriptional activity stimulated by H-ras-activated protein kinase distinct from JNK and ERK. Nature 371: 171–175, 1995Google Scholar
  72. 72.
    Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry MJ, Waterfield MD, Downward J: Phosphatidylinositol-3-OH kinase as a direct target of ras. Nature 370: 527–532, 1994Google Scholar
  73. 73.
    Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, Fukusawa K, Vande Woude GF, Ahn NG: Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265: 966–970, 1994Google Scholar
  74. 74.
    Bell SM, Connoly DC, Maihle NJ, Degen JL: Differential modulation of plasminogen activator gene expression by oncogene-encoded protein tyrosine kinases. Mol Cell Biol 13: 5888–5897, 1993Google Scholar
  75. 75.
    Domann FE, Levy JP, Birrer MJ, Bowden GT: Stable expression of a c-JUN deletion mutant in two malignant mouse epidermal cell lines blocks tumor formation in nude mice. Cell Growth and Differentiation 5: 9–16, 1994Google Scholar
  76. 76.
    Brown PH, Alani R, Preis LH, Szabo E, Birrer MJ: Stable expression of a c-JUN deletion mutant in two malignant mouse epidermal cell lines blocks tumor formation in nude mice. Oncogene 8: 877–886, 1993Google Scholar
  77. 77.
    Robbins DJ, Zhen E, Owaki H, Vanderbilt CA, Ebert D, Geppert TD, Cobb MH: Regulation and properties of extracellular signal-regulated protein kinases 1 and 2 in vitro. J Biol Chem 268: 5097–5106, 1993Google Scholar
  78. 78.
    Shin DM, Ro JY, Hong WK, Hittelman WN: Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 54: 3153–3159, 1994Google Scholar
  79. 79.
    Grandis J, Tweardy DJ: Elevated levels of transforming growth factor a and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 53: 3579–3584, 1993Google Scholar
  80. 80.
    Sturgis E, Sacks PG, Masui H, Mendelsohn J, Schanz SP: Effects of antiepidermal growth factor receptor antibody 528 on the proliferation and differentiation of head and neck cancer. Head and Neck Surgery 111: 633–643, 1994Google Scholar
  81. 81.
    Schechter AL, Hung M, Vaidyanathan L, Weinberg RA, Yang-Feng TL, Francke U, Ullrich A, Coussens L: The neugene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science 229: 976–978, 1985Google Scholar
  82. 82.
    Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N, Saito T, Toyoshima K: Similarity of protein encoded by the human c-erbB2 gene to epidermal growth factor. Nature 319: 230–234, 1986Google Scholar
  83. 83.
    Beckhardt RN, Kiyokawa N, Liu TJ, Hung M, El-Naggar A. Clayman GL: Neu oncogene in head and neck squamous cell carcinoma. Proceedings of the American Association for Cancer Research 35: 153, 1994Google Scholar
  84. 84.
    Bongiorno PF, Whyte RI, Lesser EJ, Moore JH, Orringer MB, Beer DG: Alterations of K-ras, p53, and erbB2/neu in human lung adenocarcinomas. Journal of Thoracic Cardiovascular Surgery 107: 590–595, 1994Google Scholar
  85. 85.
    Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer. Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177–182, 1987Google Scholar
  86. 86.
    Mitra AB, Murty VVVS, Pratap M, Sodhani P, Chaganti RSK: ERBB2 (HER2/neu) oncogene is frequently amplified in squamous cell carcinoma of the uterine cervix. Cancer Res 54: 637–639, 1994Google Scholar
  87. 87.
    Lacroix H, Iglehart JD, Skinner MA, Krauss MH: Overexpression of erbB2 or EGF-receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastasis. Oncogene 4: 145–151, 1989Google Scholar
  88. 88.
    Yu D, Hung MC: Expression of activated ras neu oncogene is sufficient to induce experimental metastasis in 3T3 cells. Oncogene 6: 1991–1996, 1991Google Scholar
  89. 89.
    Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ: Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 89: 10578–10582, 1992Google Scholar
  90. 90.
    Hou L, Shi D, Zhang HZ, Hung MC, Ling D: Oral cancer progression an c-erbB-2/neu proto-oncogene expression. Cancer Letters 65: 215–220, 1992Google Scholar
  91. 91.
    Gohji K, Nakajima M, Fabra A, Bucana CD, von Eschenbach AC, Tsuruo T, Fidler IJ: Regulation of gelatinase production in metastatic renal cell carcinoma by organ-specific fibroblasts. Japanese Journal of Cancer Research 85: 152–160, 1994Google Scholar
  92. 92.
    Matsumoto K, Horikoshi M, Rikimaru K, Enomoto S: A study of an in vitro model for invasion of oral squamous cell carcinoma. J Oral Path Med 18: 498–501, 1989Google Scholar
  93. 93.
    Lengyel E, Gum R, Juarez J, Clayman G, Seiki M, Sato H, Boyd D: Induction of Mr 92.000 type IV collagenase expression in a squamous cell carcinoma cell line by fibroblasts. Cancer Res 55: 963–967, 1995Google Scholar
  94. 94.
    Hurwitz A, Dushnik M, Solomon H, Ben-Chetrit A, Finci-Yeheskel Z, Milwidsky A, Mayer M, Adashi EY, Yagel S: Cytokine-mediated regulation of rat ovarian function: interleukin-1 stimulates the accumulation of a 92-kilodalton gelatinase. Endocrinology 132: 2709–2714, 1993Google Scholar
  95. 95.
    Shima I, Sasaguri Y, Kusukawa J, Nakano R, Yamana H, Fufita H, Kakegawa T, Morimatsu M: Production of matrix metalloproteinase 9 (92-kDa gelatinase) by human oesophageal squamous cell carcinoma in response to epidermal growth factor. Br J Cancer 67: 721–727, 1993Google Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • Douglas Boyd
    • 1
  1. 1.Department of Head and Neck Surgery/Tumor BiologyUniversity of Texas, M.D. Anderson Cancer CenterUSA

Personalised recommendations